Injuries & Orthopedics
Peptides for Osteoporosis & Bone Density: Ranked by Evidence (2026)
A clinical, evidence-graded ranking of peptide drugs for osteoporosis — from the FDA-approved PTH-receptor anabolics with Grade A fracture-reduction RCTs to salmon calcitonin's regulatory demotion and the entirely unproven grey-market 'bone peptides.'
Evidence-gradedFDA-approved anabolicsFracture-reduction RCTsPTH-receptor peptidesGrey-market vs proven
The quick verdict
For osteoporosis, the honest answer inverts the usual peptide story. The highest-grade evidence belongs to FDA-approved PTH-receptor anabolics that genuinely BUILD bone, with Grade A fracture-reduction RCTs. Salmon calcitonin has been regulatory-demoted, and every grey-market 'bone peptide' is preclinical or anecdotal at best. Here is each one graded honestly.
- Best overall
- Teriparatide (PTH 1-34) — The single most evidence-supported peptide for osteoporosis and the first FDA-approved bone anabolic — ~65% vertebral and ~53% non-vertebral fracture reduction vs placebo, a head-to-head win over risedronate (VERO), and no longer carrying a boxed warning.
- Best value
- Salmon calcitonin (Miacalcin/Fortical) — An old, inexpensive FDA-approved peptide — but its osteoporosis case has collapsed: the label says fracture-reduction efficacy is 'not demonstrated,' it carries a malignancy signal, and its only real niche now is short-term acute vertebral-fracture pain.
- Best for Osteoporotic patients (women or men) needing maximal fracture reduction with less hypercalcemia
- Abaloparatide (Tymlos) — Grade A second-generation PTHR1 anabolic that cut new vertebral fractures ~86% vs placebo in ACTIVE, with a non-vertebral edge and less hypercalcemia than teriparatide — though its overall advantage is modest, and it still carries a boxed warning.
How we evaluated
We ranked every peptide with published osteoporosis or bone-density data strictly by the strength of its HUMAN evidence for a real bone endpoint — fracture reduction or bone-mineral-density gain. FDA-approved drugs with placebo-controlled randomized-trial evidence rank above compounds whose bone data are animal-stage or anecdotal only. Grades are never inflated: a coherent mechanism or a rodent result is not treated as human proof, and we say so explicitly for each compound. We also flag regulatory demotions and sport status, because an honest assessment includes legality.
- Human evidence strength. Completed placebo-controlled RCTs and meta-analyses outrank observational, animal, and in-vitro data. Grade A requires human RCT/meta-analysis for a bone endpoint; Grade C means preclinical only; Grade D is anecdotal/marketing.
- Fracture-reduction endpoint. We grade the specific proven endpoint — vertebral, non-vertebral, and clinical fracture reduction — rather than surrogate BMD alone, and distinguish anabolic (bone-building) from antiresorptive action.
- Regulatory & sport status. FDA approval, label warnings, regulatory demotions, and WADA/anti-doping status are reported for each compound, because legality and boxed warnings are part of an honest assessment.
- Safety and contraindications. Condition-specific risks (hypercalcemia, osteosarcoma signals, malignancy warnings, product-purity hazards) are weighed alongside efficacy.
Rating scale: 5 = FDA-approved with Grade A human RCT fracture-reduction evidence; 3 = approved but weak/legacy/regulatory-demoted (Grade B); 2 or below = not an available/approved osteoporosis therapy, or preclinical/anecdotal only (Grade C/D).
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Teriparatide (recombinant human PTH 1-34) | A | 5.0 | Postmenopausal, male, or glucocorticoid-induced osteoporosis where an anabolic agent is indicated to reduce fracture risk | Prescription; varies by insurer/pharmacy |
| 2 | Abaloparatide (synthetic PTHrP 1-34 analog) | A | 4.5 | Osteoporotic patients (women or men) needing strong vertebral- and non-vertebral-fracture reduction with less hypercalcemia than teriparatide | Prescription (Tymlos); varies by insurer/pharmacy |
| 3 | Salmon calcitonin (Miacalcin / Fortical) | B | 2.5 | Short-term analgesia in acute painful vertebral fracture when first-line agents are unsuitable — not long-term bone-density therapy | Prescription (Miacalcin/Fortical); low-cost generic available |
| 4 | Full-length PTH 1-84 (Preotact / Preos) | A | 2.0 | Context and completeness only — understanding that strong anabolic trial data did not translate into an accessible osteoporosis drug | Not available/approved for osteoporosis |
| 5 | Grey-market 'bone peptides' (BPC-157, GH secretagogues, MOTS-c, GHK-Cu) | D | 1.0 | Understanding why grey-market bone peptides do NOT qualify as osteoporosis therapy — not for treatment | Sold as research chemicals; no legitimate osteoporosis price |
Teriparatide (recombinant human PTH 1-34)
The most evidence-backed bone peptide — Grade A fracture reduction, FDA-approved, boxed warning removed
Teriparatide is the biologically active N-terminal 1-34 fragment of human parathyroid hormone, marketed as Forteo and now several biosimilars, and it is the single most evidence-supported peptide for osteoporosis. It was the first FDA-approved bone anabolic. The mechanism is dose-timing-dependent: continuous PTH elevation drives net bone loss, but intermittent, once-daily PTHR1 stimulation transiently activates osteoblasts more than osteoclasts, opening a net anabolic window in which new bone forms. The pivotal Fracture Prevention Trial showed roughly a 65 percent reduction in new vertebral fractures and about 53 percent in non-vertebral fragility fractures versus placebo, and a meta-analysis of 13 studies found teriparatide significantly reduced both vertebral (OR 0.40) and non-vertebral fracture risk relative to bisphosphonate comparators. The head-to-head VERO trial in severe osteoporosis showed new vertebral fractures in 5.4 percent on teriparatide versus 12.0 percent on risedronate. Dosing in labeling is 20 micrograms subcutaneously once daily; in November 2020 the FDA removed both the two-year lifetime cap and the osteosarcoma boxed warning after 15 years of surveillance showed no excess. Gains are typically consolidated by following with an antiresorptive.
Strengths
- Grade A human RCT evidence: ~65% vertebral and ~53% non-vertebral fracture reduction vs placebo (Fracture Prevention Trial)
- First anabolic proven to beat an antiresorptive head-to-head on fracture endpoints (VERO: 5.4% vs 12.0% new vertebral fractures vs risedronate)
- FDA-approved (Forteo, biosimilars) with the longest track record; osteosarcoma boxed warning and 2-year cap removed in 2020
- Genuinely bone-anabolic — builds new bone rather than merely slowing loss
Weaknesses
- Injectable prescription drug, not a lifestyle peptide; anabolic effect wanes on discontinuation and BMD is lost without a follow-on antiresorptive
- Transient hypercalcemia, hypercalciuria, early orthostatic hypotension, nausea, leg cramps, dizziness
- Contraindicated where baseline osteosarcoma risk is elevated (Paget's disease, prior skeletal radiation, bone metastases, open epiphyses); WADA-prohibited in sport
- Best for
- Postmenopausal, male, or glucocorticoid-induced osteoporosis where an anabolic agent is indicated to reduce fracture risk
- Pricing
- Prescription; varies by insurer/pharmacy
Source: Teriparatide comparative meta-analysis (catalogs Fracture Prevention Trial), PMC 2024
Abaloparatide (synthetic PTHrP 1-34 analog)
Grade A second-generation anabolic — ~86% vertebral-fracture reduction, non-vertebral edge, less hypercalcemia
Abaloparatide, marketed as Tymlos, is a 34-amino-acid synthetic analog of parathyroid hormone-related protein, engineered to favor the transient RG conformation of the PTH1 receptor, which is thought to give it a longer anabolic window with less calcium mobilization and bone resorption than teriparatide. It is essentially co-equal Grade A evidence. In the pivotal ACTIVE trial, which randomized 2,463 postmenopausal women to abaloparatide, placebo, or open-label teriparatide for 18 months, abaloparatide reduced new vertebral fractures roughly 86 percent versus placebo, compared with about 80 percent for teriparatide, and it also significantly reduced non-vertebral, major osteoporotic, and clinical fractures, including a reduction in major osteoporotic fractures versus teriparatide itself. The open-label ACTIVExtend phase transitioned patients to alendronate with sustained fracture benefit, validating the anabolic-then-antiresorptive sequence. A network meta-analysis ranked abaloparatide favorably, and NNT analyses suggest a non-vertebral advantage. It was FDA-approved for postmenopausal women in 2017 and extended to men with osteoporosis in December 2022. Dosing is 80 micrograms subcutaneously once daily. The honest counterpoint: its superiority over teriparatide is modest, and unlike teriparatide it still carries a boxed warning for osteosarcoma and a roughly two-year cumulative-use recommendation.
Strengths
- Grade A ACTIVE trial: ~86% reduction in new vertebral fractures vs placebo, plus non-vertebral, clinical, and major osteoporotic fracture reductions
- Non-vertebral / major-osteoporotic-fracture edge over teriparatide, and generally less hypercalcemia
- FDA-approved for postmenopausal (2017) and, since December 2022, male osteoporosis; gains preserved when sequenced into an antiresorptive (ACTIVExtend)
- Second-generation RG-selective PTHR1 pharmacology — a wider anabolic window in theory
Weaknesses
- Still carries an osteosarcoma boxed warning and ~2-year cumulative PTH-analog cap (regulatory asymmetry vs teriparatide, whose warning was removed)
- Advantage over teriparatide is modest, not dramatic; injectable prescription drug requiring monitoring
- Hypercalcemia, hypercalciuria, dizziness, orthostatic hypotension, palpitations, nausea; a transdermal patch failed non-inferiority so the injection remains standard
- Best for
- Osteoporotic patients (women or men) needing strong vertebral- and non-vertebral-fracture reduction with less hypercalcemia than teriparatide
- Pricing
- Prescription (Tymlos); varies by insurer/pharmacy
Salmon calcitonin (Miacalcin / Fortical)
Once-important antiresorptive peptide, now regulatory-demoted — label says efficacy 'not demonstrated'
Salmon calcitonin is a 32-amino-acid peptide hormone, far more potent at the human calcitonin receptor than the native form, available as an intranasal spray and injection. It is antiresorptive, not anabolic, binding osteoclast calcitonin receptors to acutely suppress bone resorption. It earns inclusion because it is FDA-approved and once had genuine RCT data, but its osteoporosis story has reversed. The PROOF study reported that intranasal calcitonin 200 IU per day reduced vertebral fracture risk by about 36 percent versus placebo, but the trial had high dropout, an inconsistent dose-response (the 100 and 400 IU arms did not show the effect), and no non-vertebral or hip fracture benefit, so the data are widely regarded as weak. Critically, in March 2014 the FDA revised all salmon-calcitonin labels to state that meta-analyses suggest an increased risk of malignancies, restricted the indication to patients for whom alternatives are unsuitable, and added that fracture-reduction efficacy has not been demonstrated. A 2025 pharmacovigilance and RCT meta-analysis continued to flag an unfavorable benefit-risk balance for long-term use in the elderly. Where it retains a niche is a genuine short-term analgesic effect in acute painful vertebral fracture, not long-term bone-density maintenance.
Strengths
- FDA-approved with a genuine RCT (PROOF: ~36% fewer vertebral fractures at 200 IU intranasal) and a defined analgesic niche
- Real short-term pain relief in acute painful vertebral fracture
- Inexpensive, long-established, and available as a non-injectable intranasal spray
Weaknesses
- FDA label states fracture-reduction efficacy 'has not been demonstrated'; PROOF had high dropout, inconsistent dose-response, and no hip/non-vertebral benefit
- Pooled malignancy signal (any-cancer OR ~1.5–1.6) drove a 2014 regulatory demotion to last-line use
- Rhinitis/epistaxis/nasal irritation, nausea, flushing; largely obsolete for bone density in modern practice
- Best for
- Short-term analgesia in acute painful vertebral fracture when first-line agents are unsuitable — not long-term bone-density therapy
- Pricing
- Prescription (Miacalcin/Fortical); low-cost generic available
Source: Overman et al., 2013 — salmon calcitonin & cancer risk (FDA action context)
Full-length PTH 1-84 (Preotact / Preos)
Grade A anabolic evidence, but NOT an available FDA-approved osteoporosis therapy
Recombinant full-length parathyroid hormone, PTH(1-84), is bone-anabolic and had positive randomized-trial data for osteoporosis: the TOP study, which enrolled 2,532 women over 18 months, showed PTH(1-84) at 100 micrograms per day reduced new or worsened vertebral fractures by about 61 percent versus placebo, though without a non-vertebral benefit. Mechanistically it shares the intermittent-PTH anabolic principle with teriparatide and abaloparatide. It is included here for completeness because its efficacy evidence is genuinely Grade A, but the crucial practical point is that it is not a current osteoporosis therapy. The US new drug application, Preos, was not approved because of hypercalcemia concerns, and the European product, Preotact and later Natpara, is not an available osteoporosis option. PTH(1-84) as Natpara survives only for hypoparathyroidism, not for building bone density in osteoporosis. For anyone seeking a peptide for osteoporosis, this means the two usable PTH-class anabolics remain teriparatide and abaloparatide; PTH(1-84) is a cautionary example of strong trial data that never became an accessible osteoporosis drug.
Strengths
- Grade A anabolic RCT data for osteoporosis (TOP study: ~61% reduction in new/worsened vertebral fractures vs placebo)
- Shares the validated intermittent-PTH anabolic mechanism with teriparatide and abaloparatide
- Full-length native-hormone approach — biologically well characterized
Weaknesses
- NOT an available FDA-approved osteoporosis therapy — the US NDA (Preos) was not approved over hypercalcemia concerns
- The EU product (Preotact/Natpara) is not an osteoporosis option; PTH(1-84) survives only for hypoparathyroidism
- No non-vertebral fracture benefit in the pivotal trial; effectively unavailable for bone-density indications
- Best for
- Context and completeness only — understanding that strong anabolic trial data did not translate into an accessible osteoporosis drug
- Pricing
- Not available/approved for osteoporosis
Grey-market 'bone peptides' (BPC-157, GH secretagogues, MOTS-c, GHK-Cu)
The peptides people usually mean — and the ones with zero human osteoporosis evidence (Grade D)
When people search for peptides for bone density, they usually mean grey-market research peptides such as BPC-157, TB-500, GHK-Cu, MOTS-c, KPV, and the GH secretagogues like CJC-1295, ipamorelin, sermorelin, tesamorelin, and MK-677 (ibutamoren). For osteoporosis specifically, none of these has any human randomized controlled trial showing it reduces fracture risk or increases bone density. Their bone-relevant data are preclinical at best, extrapolated from rodent fracture-callus or tendon and ligament models, and often purely anecdotal or marketing claims. None is FDA-approved for any bone indication. The GH secretagogues have a plausible-sounding rationale, since GH and IGF-1 influence bone turnover, but there is no controlled human evidence that they prevent osteoporotic fractures, and most are unapproved substances on the WADA prohibited list. Claims that these compounds heal bone or build bone density in osteoporosis run far ahead of the evidence. We grade this group D because the human osteoporosis evidence is effectively absent, and the mechanistic extrapolations do not constitute human bone proof. Anyone with osteoporosis should treat a build-bone-with-peptides sales pitch involving these compounds as unproven, and should look instead to the FDA-approved PTH-class anabolics discussed above.
Strengths
- Some (e.g. BPC-157, GHK-Cu) have coherent regenerative mechanisms in animal models — of scientific interest
- Widely discussed, so understanding why they fail the osteoporosis bar is genuinely useful
- GH/IGF-1 biology does influence bone turnover in principle
Weaknesses
- Zero human osteoporosis RCTs — no evidence any of these reduces fracture risk or raises bone density (Grade D)
- None FDA-approved for any bone indication; sold as research chemicals with product-purity, endotoxin, and dosing-accuracy hazards
- Most GH secretagogues are on the WADA prohibited list; bone claims extrapolate from rodent models that do not transfer to human osteoporosis
- Best for
- Understanding why grey-market bone peptides do NOT qualify as osteoporosis therapy — not for treatment
- Pricing
- Sold as research chemicals; no legitimate osteoporosis price
Source: WADA Prohibited List context — peptide hormones / TUE (BSCG)
Frequently asked
Are peptides a good treatment for osteoporosis?
Yes, but only the specific FDA-approved PTH-receptor peptide drugs, teriparatide and abaloparatide. These are among the most effective osteoporosis therapies in existence and carry Grade A fracture-reduction randomized-controlled-trial evidence. They are genuinely bone-anabolic, meaning they build new bone rather than merely slowing its loss. The important caveat is that the grey-market bone peptides sold online, such as BPC-157, GH secretagogues, and MOTS-c, have no human osteoporosis evidence at all; their bone-relevant data are preclinical or purely anecdotal. So peptides can be an excellent osteoporosis treatment, but only the FDA-approved PTH-class anabolics prescribed and monitored by a clinician, not the research-chemical peptides.
Teriparatide vs abaloparatide — which is better?
Both are Grade A anabolics and the choice is individualized. In the ACTIVE trial abaloparatide reduced new vertebral fractures roughly 86 percent versus about 80 percent for teriparatide, each against placebo, and abaloparatide showed an edge on non-vertebral and major osteoporotic fractures plus somewhat less hypercalcemia. Number-needed-to-treat analyses suggest a non-vertebral advantage for abaloparatide. However, teriparatide has the longest track record and, since November 2020, no longer carries a boxed warning, while abaloparatide retains its osteosarcoma boxed warning. Neither is a clear-cut winner; the decision weighs side-effect profile, warnings, cost, and patient factors, and belongs with a treating clinician.
Why are PTH-analog peptides limited to about two years?
The anabolic window is finite, and the historical rat-osteosarcoma finding originally capped cumulative use. Abaloparatide's label still recommends roughly two years of cumulative PTH-analog exposure, combined across teriparatide and abaloparatide. Teriparatide's hard two-year lifetime cap was actually removed by the FDA in November 2020 after fifteen years of surveillance showed no excess osteosarcoma, but anabolics are still typically used time-limited. Critically, the anabolic effect wanes after discontinuation, and bone-mineral-density gains are lost unless an antiresorptive such as alendronate or denosumab follows. This build-then-lock sequence, validated in the ACTIVExtend and PaTH extension studies, is why courses are finite rather than permanent.
Is salmon calcitonin still recommended for osteoporosis?
Largely no. Salmon calcitonin's osteoporosis story reversed over time. The PROOF study reported roughly 36 percent fewer vertebral fractures at 200 IU intranasal, but it had high dropout, an inconsistent dose-response, and no non-vertebral or hip fracture benefit, so the data are considered weak. In March 2014 the FDA revised all salmon-calcitonin labels to state that meta-analyses suggest an increased malignancy risk, restricted the indication to patients for whom alternatives are unsuitable, and added that fracture-reduction efficacy has not been demonstrated. It retains a narrow role only for short-term analgesia in acute painful vertebral fracture, not for long-term bone-density maintenance.
Do BPC-157 and other grey-market peptides build bone density?
There is no human evidence that they do. Grey-market bone peptides such as BPC-157, TB-500, GHK-Cu, MOTS-c, and the GH secretagogues (CJC-1295, ipamorelin, sermorelin, MK-677) have no human randomized controlled trials showing they reduce fracture risk or increase bone density in osteoporosis. Their bone-relevant data are preclinical, from rodent fracture-callus or tendon models, or purely anecdotal marketing claims. None is FDA-approved for any bone indication. Extrapolating rodent healing to human osteoporosis is not evidence, and most GH secretagogues are also on the WADA prohibited list. Any build-bone-with-peptides sales pitch involving these compounds should be treated as unproven.
Do PTH peptides also reduce hip fractures?
The strongest and most consistent benefit of the PTH-receptor anabolics is for vertebral fractures, along with overall clinical and non-vertebral fractures. Hip-fracture-specific reduction is less firmly established, because the pivotal trials were not powered for hip endpoints. Among the anabolics, the clearest non-vertebral fracture benefit belongs to abaloparatide, as shown in the ACTIVE trial and supported by network meta-analysis. So while these peptides substantially cut vertebral and overall fracture risk, patients and clinicians should not assume a proven, dedicated hip-fracture reduction from the pivotal data. Fracture-risk profile and site should factor into individualized therapy decisions with a clinician.